Intellia Therapeutics Closes $194.6 Million Public Offering to Fund Operations into 2028

On April 28, 2026, Intellia Therapeutics entered into an underwriting agreement for a public offering of 16,744,187 shares of common stock at $10.75 per share. The underwriters fully exercised their 30-day option to purchase an additional 2,511,628 shares. The offering closed on April 30, 2026, generating approximately $194.6 million in net proceeds. Intellia intends to use the capital to advance clinical development, prepare for the commercial launch of lead programs, and fund general corporate purposes. The company expects its total cash position, which includes approximately $517.2 million as of March 31, 2026, and the new offering proceeds, to fund operations at least into 2028. This projection excludes potential revenue from lonvoguran ziclumeran, which is anticipated for potential approval and launch in the first half of 2027 for the treatment of hereditary angioedema. Additionally, the company reported raising $33.6 million through an "at the market" equity program during the first quarter of 2026.